All studies
RecruitingTherapeutic confirmatory (Phase III)Interventional

Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-onset (Focal) Seizures

Focal seizures are epileptic fits that start in one specific part of the brain. While there are treatments available, they do not work well for every child. This study looks at an epilepsy medicine called cenobamate to see if it can safely help children and young people. In this study, all participants receive cenobamate as either a tablet or a liquid suspension. Doctors will track how many seizures happen over a 12-month period to see if the medicine reduces them or stops them completely. Researchers will also monitor safety very closely. They will check for any unwanted side effects, watch the child's growth, and assess their mood, behaviour, and coordination. They will also ask young people how the medicine tastes and how easy it is to take. Taking part is voluntary, and families can leave at any time.

At a glance

Status
Recruiting
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Sk Life Science Inc.
Enrolment target
74
Start
25 Apr 2024

What is this study about?

Epilepsy is a condition that affects the brain, causing recurring seizures. In focal seizures, the seizure activity begins in one particular area of the brain. For many children and teenagers, finding the right medicine can be difficult because existing treatments do not always stop their seizures, or they may cause unpleasant side effects. When standard medicines do not work well enough, doctors look for new, effective options.

Cenobamate is an anti-seizure medicine that has already been tested and approved for certain adults with epilepsy. This study aims to find out if it is safe, gentle, and effective for children and young people. Because this is an 'open-label' trial, there is no dummy medicine (placebo). Every child in the study will receive cenobamate, given either as tablets or as a flavoured liquid.

Over the course of a year, the research team will carefully track how the medicine affects seizure frequency. They want to see if children experience fewer seizures or become completely seizure-free. At the same time, the team will monitor children's overall health, physical growth, and development. They will also measure thinking skills, mood, behaviour, and motor skills (like hand coordination) to ensure the medicine supports good quality of life.

By gathering this detailed information, the study hopes to help doctors understand the right doses for younger patients and discover whether cenobamate could become a valuable new treatment option for childhood epilepsy in the UK and worldwide.

Key takeaways

  • The study tests an epilepsy medicine called cenobamate in children and teenagers with focal seizures.
  • All participants receive the study medicine; no placebo is used.
  • The medicine is available as both tablets and a liquid suspension.
  • Doctors will monitor seizure numbers, physical growth, thinking skills, and side effects over at least one year.
  • Joining the study is completely optional, and you can leave at any time without losing your regular medical care.

Who may be eligible?

This trial is designed for children and teenagers who have been diagnosed with focal (partial-onset) seizures and still experience fits despite their current treatments. Both boys and girls can take part.

To join, participants must be able to attend regular clinic visits with a parent or carer. They will need to be willing to take the study medicine as directed, either as a tablet or as a liquid.

Children may not be able to join if they have certain other severe medical conditions, specific heart problems, or allergies to similar medicines. A doctor will carefully review each child's medical history and current epilepsy treatments before deciding if the study is safe and suitable for them.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. My child is a child or teenager with a diagnosis of focal (partial-onset) seizures.
  2. My child still experiences seizures despite their current treatment plan.
  3. A parent or guardian is able to attend regular hospital appointments and keep a seizure diary.
  4. My child can safely take medicine either as a swallowed tablet or a liquid.
  5. My child is willing to try a new medicine under close medical supervision.
Answer every question to see your result.

What does participation involve?

Taking part usually lasts for at least one year. During this time, the doctor will start your child on a low dose of cenobamate and slowly increase it to find the best amount that controls seizures with the fewest side effects. The medicine is taken daily by mouth, either as tablets or as a liquid.

Families will need to keep a daily seizure diary to record any fits. You will visit the clinic regularly so doctors can check your child's general health, blood pressure, height, and weight. The team will run routine blood tests, heart checks (ECGs), and ask questions about your child's mood and daily behaviour.

Children will also do simple coordination checks, such as placing small pegs into a board, and answer quick questions about how the medicine tastes and how easy it is to swallow. After the first year, doctors will discuss the next steps for your child's ongoing epilepsy care.

Potential risks and benefits

The main hope of taking part is that cenobamate may help reduce how often your child has seizures, or even stop them entirely, though this cannot be guaranteed. The information collected will also help other children with epilepsy in the future. However, there is a risk of side effects, such as sleepiness, dizziness, or changes in mood, and taking part involves extra hospital visits and tests. Taking part is completely voluntary, and you can withdraw your child from the study at any point without it affecting their normal NHS care.

Locations (4)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Germany
  • —
    Unverified
    Hungary
  • —
    Unverified
    Poland
  • —
    Unverified
    Spain

Common questions

What does 'open-label' mean?

It means both you and the study doctors will know that your child is taking the real medicine. There is no fake medicine or placebo used in this study.

Can my child take their regular epilepsy medicines during the study?

In most cases, yes. Cenobamate is usually added to existing medicines, but the study doctor will check all current treatments to make sure they are safe to take together.

What happens if my child cannot swallow tablets?

The study offers cenobamate as a liquid suspension as well as tablets, making it easier for younger children or those who dislike pills to take.

Will taking part cure my child's epilepsy?

No, this trial is not a cure. The medicine is designed to control and reduce the number of seizures a child experiences.

Can we stop taking part if we change our minds?

Yes. You can leave the study at any time. The study doctor will guide you on how to reduce the medicine safely so seizures do not suddenly return.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Open-Label Safety and Efficacy Study of Cenobamate (YKP3089)…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.